Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novus Therapeutics Inc (NVUS)

Novus Therapeutics Inc (NVUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,309
  • Shares Outstanding, K 16,070
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,010 K
  • 60-Month Beta 3.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.65
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.87
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/11/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +285,528.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4398 +5.25%
on 07/14/20
0.6110 -24.24%
on 07/22/20
+0.0008 (+0.17%)
since 07/02/20
3-Month
0.4200 +10.21%
on 05/06/20
1.4500 -68.08%
on 05/28/20
-0.1771 (-27.67%)
since 05/01/20
52-Week
0.2500 +85.16%
on 03/20/20
1.4500 -68.08%
on 05/28/20
-0.3146 (-40.46%)
since 08/02/19

Most Recent Stories

More News
Global Otitis Media Pipeline Research Monitor 2020 with Profiles of 12 Companies Including Blue Water Vaccines, Lee's Pharma, Merck, Novus Therapeutics, and Yuhan Corp - ResearchAndMarkets.com

The "Otitis Media Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

MRK : 83.50 (+4.06%)
NVUS : 0.4664 (+2.55%)
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media

--Company engages financial advisors to explore strategic options

NVUS : 0.4664 (+2.55%)
Novus Therapeutics Reports First Quarter 2020 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for...

NVUS : 0.4664 (+2.55%)
Thinking about buying stock in Applied DNA Sciences, Novus Therapeutics, Riot Blockchain, Upwork, or Delta Air Lines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APDN, NVUS, RIOT, UPWK, and DAL.

APDN : 9.87 (-1.30%)
DAL : 24.75 (-0.88%)
NVUS : 0.4664 (+2.55%)
RIOT : 3.38 (+28.03%)
UPWK : 16.87 (+12.32%)
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial results for...

NVUS : 0.4664 (+2.55%)
Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has completed...

NVUS : 0.4664 (+2.55%)
Novus Therapeutics Provides Update on OP0201

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the ongoing...

NVUS : 0.4664 (+2.55%)
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the agreement...

NVUS : 0.4664 (+2.55%)
Novus Therapeutics to Participate in Two Investor Conferences

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company...

NVUS : 0.4664 (+2.55%)
Novus Therapeutics Reports Third Quarter 2019 Financial Results

-- Data from ongoing phase 2a study C-006 expected in the first half of 2020 --

NVUS : 0.4664 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NVUS with:

Business Summary

Novus Therapeutics, Inc. is a pharmaceutical company. It focused on the acquisition, development and commercialization of ear, nose and throat products. The company's platform consists of OP-01 Foam Platform and OP-02 Surfactant Program. Novus Therapeutics, Inc., formerly known as Tokai Pharmaceuticals...

See More

Key Turning Points

2nd Resistance Point 0.4874
1st Resistance Point 0.4711
Last Price 0.4664
1st Support Level 0.4465
2nd Support Level 0.4382

See More

52-Week High 1.4500
Fibonacci 61.8% 0.9916
Fibonacci 50% 0.8500
Fibonacci 38.2% 0.7084
Last Price 0.4664
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar